Cargando…

Prognostic value of metformin in cancers: An updated meta-analysis based on 80 cohort studies

Experiments have shown that metformin can inhibit cancer cell growth, but clinical observations have been inconsistent, so we pooled the currently available data to evaluate the impact of metformin on cancer survival and progression. METHODS: PubMed, web of science, Embase, and Cochrane databases we...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jing, Yang, Hang, Cao, Ling, Yin, Yuzhen, Shen, Ying, Zhu, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750609/
https://www.ncbi.nlm.nih.gov/pubmed/36626437
http://dx.doi.org/10.1097/MD.0000000000031799
_version_ 1784850293214674944
author Yang, Jing
Yang, Hang
Cao, Ling
Yin, Yuzhen
Shen, Ying
Zhu, Wei
author_facet Yang, Jing
Yang, Hang
Cao, Ling
Yin, Yuzhen
Shen, Ying
Zhu, Wei
author_sort Yang, Jing
collection PubMed
description Experiments have shown that metformin can inhibit cancer cell growth, but clinical observations have been inconsistent, so we pooled the currently available data to evaluate the impact of metformin on cancer survival and progression. METHODS: PubMed, web of science, Embase, and Cochrane databases were searched. Pooled hazard ratios (HRs) were identified using a random-effects model to estimate the strength of the association between metformin and survival and progression in cancer patients. RESULTS: We incorporated 80 articles published from all databases which satisfied the inclusion criterion. It showed that metformin was associated with better overall survival (hazard ratio [HR] = 0. 81; 95% confidence interval [CI]: [0.77–0.85]) and cancer-specific survival (HR = 0.79; 95% CI: [0.73–0.86]), and metformin was associated with progression-free survival (HR = 0.76; 95% CI: [0.66–0.87]). In patients with diabetes mellitus, the HR of overall survival was 0.79(95% CI: [0.75–0.83]), progression-free survival was 0.72(95% CI: [0.60–0.85]), and the cancer-specific survival was 0.76(95% CI: [0.68–0.86]). It was proposed that metformin can improve the prognosis of cancer patients with diabetes mellitus. CONCLUSION: Based on cohort studies, metformin therapy has potential survival benefits for patients with malignancy, especially with the greatest benefits seen in breast cancer on overall survival, progression-free survival, and cancer-specific survival. And metformin also showed potential benefits in cancer-specific survival in colorectal and prostate cancer.
format Online
Article
Text
id pubmed-9750609
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-97506092022-12-28 Prognostic value of metformin in cancers: An updated meta-analysis based on 80 cohort studies Yang, Jing Yang, Hang Cao, Ling Yin, Yuzhen Shen, Ying Zhu, Wei Medicine (Baltimore) 5700 Experiments have shown that metformin can inhibit cancer cell growth, but clinical observations have been inconsistent, so we pooled the currently available data to evaluate the impact of metformin on cancer survival and progression. METHODS: PubMed, web of science, Embase, and Cochrane databases were searched. Pooled hazard ratios (HRs) were identified using a random-effects model to estimate the strength of the association between metformin and survival and progression in cancer patients. RESULTS: We incorporated 80 articles published from all databases which satisfied the inclusion criterion. It showed that metformin was associated with better overall survival (hazard ratio [HR] = 0. 81; 95% confidence interval [CI]: [0.77–0.85]) and cancer-specific survival (HR = 0.79; 95% CI: [0.73–0.86]), and metformin was associated with progression-free survival (HR = 0.76; 95% CI: [0.66–0.87]). In patients with diabetes mellitus, the HR of overall survival was 0.79(95% CI: [0.75–0.83]), progression-free survival was 0.72(95% CI: [0.60–0.85]), and the cancer-specific survival was 0.76(95% CI: [0.68–0.86]). It was proposed that metformin can improve the prognosis of cancer patients with diabetes mellitus. CONCLUSION: Based on cohort studies, metformin therapy has potential survival benefits for patients with malignancy, especially with the greatest benefits seen in breast cancer on overall survival, progression-free survival, and cancer-specific survival. And metformin also showed potential benefits in cancer-specific survival in colorectal and prostate cancer. Lippincott Williams & Wilkins 2022-12-09 /pmc/articles/PMC9750609/ /pubmed/36626437 http://dx.doi.org/10.1097/MD.0000000000031799 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle 5700
Yang, Jing
Yang, Hang
Cao, Ling
Yin, Yuzhen
Shen, Ying
Zhu, Wei
Prognostic value of metformin in cancers: An updated meta-analysis based on 80 cohort studies
title Prognostic value of metformin in cancers: An updated meta-analysis based on 80 cohort studies
title_full Prognostic value of metformin in cancers: An updated meta-analysis based on 80 cohort studies
title_fullStr Prognostic value of metformin in cancers: An updated meta-analysis based on 80 cohort studies
title_full_unstemmed Prognostic value of metformin in cancers: An updated meta-analysis based on 80 cohort studies
title_short Prognostic value of metformin in cancers: An updated meta-analysis based on 80 cohort studies
title_sort prognostic value of metformin in cancers: an updated meta-analysis based on 80 cohort studies
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750609/
https://www.ncbi.nlm.nih.gov/pubmed/36626437
http://dx.doi.org/10.1097/MD.0000000000031799
work_keys_str_mv AT yangjing prognosticvalueofmetforminincancersanupdatedmetaanalysisbasedon80cohortstudies
AT yanghang prognosticvalueofmetforminincancersanupdatedmetaanalysisbasedon80cohortstudies
AT caoling prognosticvalueofmetforminincancersanupdatedmetaanalysisbasedon80cohortstudies
AT yinyuzhen prognosticvalueofmetforminincancersanupdatedmetaanalysisbasedon80cohortstudies
AT shenying prognosticvalueofmetforminincancersanupdatedmetaanalysisbasedon80cohortstudies
AT zhuwei prognosticvalueofmetforminincancersanupdatedmetaanalysisbasedon80cohortstudies